Revised framework for development of influenza vaccines
EMA releases third and final module for public consultation
The European Medicines Agency (EMA) has released the third module of a new overarching guideline on influenza vaccines for a three-month public consultation. With this publication, the EMA is now close to finalising the establishment of a revised regulatory framework which aims to facilitate the prompt assessment of new influenza vaccines.
The procedural guidance published today describes all regulatory pathways for the authorisation or the modification of influenza vaccines intended to be used either in seasonal, pre-pandemic or pandemic settings.
It follows the publication of a module on the quality requirements for these vaccines in April 2014 and the release of a draft module on the non-clinical and clinical requirements for public consultation in July 2014.
The new overarching guideline is intended to cover and update in one single, consolidated document all aspects of the development of influenza vaccines in all epidemiological situations, i.e. seasonal, pandemic and pre-pandemic.
It has been developed based on the experience gained from many years of seasonal vaccination campaigns, the 2009/2010 influenza A(H1N1) pandemic, requests for scientific advice received from vaccine developers and applications for marketing authorisation.
The guidance applies to vaccines for which ample regulatory experience has been gained, as well as to some novel types of vaccines.